Head-to-head · WeighScore
GoodRx vs REMEVi
The verdict
REMEVi takes it — 70.4/100 to 69.6/100, but only just.
REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated. GoodRx is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | GoodRx | REMEVi |
|---|---|---|
| WeighScore | 69.6/100 | 70.4/100 |
| Grade | C | C |
| Scorecard rank | #122 | #105 |
| Semaglutide | Not disclosed | $199/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (brand Zepbound) | $269/mo (starting dose, compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #122 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
Where it loses points
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Graded #105 · C
Strengths
- The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
- Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
- LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
- Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)
Where it loses points
- Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
- Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
- The specific compounding pharmacy is not named (described as 'NPI-verified')
- A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.